Biomarkers for T-cell immune response

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K07783
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Nippon Medical School
• Principal Investigator: Iwai Yoshiko 日本医科大学, 大学院医学研究科, 大学院教授 (90362467)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: がん免疫療法

Outline of Final Research Achievements

Although immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, only a small subset of patients experience clinical benefits with ICIs. This is because antitumor immune responses vary considerably among individuals and there is currently no good indicator to assess anti-tumor immunity in cancer patients. In this study, we measured the level of soluble PD-L1 in the blood of patients with gastric cancer and non-small cell lung cancer.

Free Research Field

免疫学

Academic Significance and Societal Importance of the Research Achievements

本研究により、がんの予後および免疫チェックポイント阻害剤の治療効果を予測に有用な新しい患者層別化マーカーの発見に至り、現在、論文発表および知的財産権取得に向けて準備を進めている。